Lipid nanoparticle delivers phenylalanine ammonia lyase mRNA to the liver leading to catabolism and clearance of phenylalanine in a phenylketonuria mouse model

Phenylketonuria (PKU) is a genetic disorder affecting around 1 in 12,000 live births (1), caused by a mutation in the phenylalanine hydroxylase (PAH) gene in the liver which facilitates the catabolism of phenylalanine (Phe). Without a functional copy of PAH, levels of Phe in the blood and tissues ri...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular genetics and metabolism reports Vol. 32; p. 100882
Main Authors:	Diaz-Trelles, Ramon, Lee, Sharon, Kuakini, Kristen, Park, Jenny, Dukanovic, Adrian, Gonzalez, Jose A., Dam, Thanhchau, Kim, Jae Heon, Vega, Jerel Boyd, Sablad, Marciano, Karmali, Priya P., Tachikawa, Kiyoshi, Chivukula, Padmanabh
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-09-2022 Elsevier
Subjects:	Lipid nanoparticles Nonviral mRNA delivery Phenylketonuria (PKU) PKU mouse model Short Communication PKU mouse model Phenylketonuria (PKU) Lipid nanoparticles Nonviral mRNA delivery
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Phenylketonuria (PKU) is a genetic disorder affecting around 1 in 12,000 live births (1), caused by a mutation in the phenylalanine hydroxylase (PAH) gene in the liver which facilitates the catabolism of phenylalanine (Phe). Without a functional copy of PAH, levels of Phe in the blood and tissues rise, resulting in potentially life-threatening damage to the central nervous system. (2) Treatment options for PKU are limited, and center around adherence to a strict PKU diet that suffers from poor patient compliance. There are two approved drugs available, one of which must be used in conjunction with the PKU diet and another that has serious immunological side effects. Here we demonstrate that the LUNAR® delivery technology is capable of delivering mRNA for a replacement enzyme, the bacterial phenylalanine ammonia lyase (avPAL), into the hepatic tissue of a PKU mouse, and that the enzyme is capable of metabolizing Phe and reducing serum levels of Phe for more than five days post-transfection. We further demonstrate the ability of LUNAR to deliver a plant-derived PAL protein with a similar impact on the level of serum Phe. Taken together these results demonstrate both the capability of LUNAR for the targeted delivery of PAL mRNA into hepatic tissue in vivo, replacing the defective PAH protein and successfully reducing serum Phe levels, thereby addressing the underlying cause of PKU symptoms. Secondly, that plant-based PAL proteins are a viable alternative to bacterial avPAL to reduce the immunogenic response. •Different PAL proteins can be expressed in cell cultures by PAL mRNA transfection.•Different chemically modified PAL mRNA can be delivered in the mouse liver in vivo using Lipid nanoparticles.•LNP-PAL mRNA treatment reduces plasma Phe levels in PKU mice.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Equal contribution
ISSN:	2214-4269 2214-4269
DOI:	10.1016/j.ymgmr.2022.100882